(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Savara's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast SVRA's revenue for 2026 to be $1,954,308,651, with the lowest SVRA revenue forecast at $1,031,175,038, and the highest SVRA revenue forecast at $3,268,710,930. On average, 7 Wall Street analysts forecast SVRA's revenue for 2027 to be $18,185,752,518, with the lowest SVRA revenue forecast at $11,365,713,822, and the highest SVRA revenue forecast at $37,256,997,098.
In 2028, SVRA is forecast to generate $32,957,721,533 in revenue, with the lowest revenue forecast at $27,040,876,601 and the highest revenue forecast at $43,757,794,746.